Xenon Pharmaceuticals Target Price

Where could XENE trade next? Consensus target price: $78.

Get informed when a big investor buys or sells

+ Follow

Share Price

$58.19

Average Target Price

$77.50

33.2% upside

2 analysts in the last 4 months

High: $81 | Low: $74

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

Date	Analyst	Price Target	Current Upside/Downside
2026-08-10	H.C. WainwrightDouglas Tsao	$74	27.2% upside
2026-08-07	RBC CapitalBrian Abrahams	$81	39.2% upside
2026-05-10	Wells FargoBenjamin Burnett	$69	18.6% upside
2026-05-08	NeedhamSerge Belanger	$78	34% upside
2026-03-10	Deutsche Bank	$90	54.7% upside
2026-03-09	RBC Capital	$80	37.5% upside
2026-03-09	JefferiesAndrew Tsai	$100	71.9% upside
2026-03-09	GuggenheimYatin Suneja	$90	54.7% upside
2026-03-09	Morgan Stanley	$97	66.7% upside
2026-03-09	Robert W. Baird	$97	66.7% upside
2026-03-09	Stifel NicolausPaul Matteis	$89	52.9% upside
2026-03-09	JefferiesAndrew Tsai	$65	11.7% upside
2026-02-23	Wolfe Research	$60	3.1% upside
2026-02-10	Stifel Nicolaus	$66	13.4% upside
2025-11-04	RBC Capital	$58	0.3% downside
2025-11-04	Cantor FitzgeraldJosh Schimmer	$55	5.5% downside
2025-11-04	Wells FargoBenjamin Burnett	$44	24.4% downside
2025-02-28	Wedbush	$42	27.8% downside
2024-10-10	Raymond JamesDanielle Brill	$50	14.1% downside
2024-10-01	H.C. WainwrightDouglas Tsao	$53	8.9% downside
2024-08-09	WedbushLaura Chico	$49	15.8% downside
2024-06-18	RBC CapitalBrian Abrahams	$55	5.5% downside
2022-12-14	Goldman Sachs	$60	3.1% upside
2022-11-28	Wells Fargo	$50	14.1% downside
2022-11-11	Guggenheim	$49	15.8% downside
2022-10-18	Raymond JamesDanielle Brill	$52	10.6% downside
2022-08-11	Leerink Partners	$46	20.9% downside
2022-08-10	RBC Capital	$46	20.9% downside
2022-06-27	Wedbush	$41	29.5% downside
2022-05-11	RBC Capital	$41	29.5% downside

Xenon Pharmaceuticals (XENE) FAQ

As of the most recent data, XENE shows a target price of $78. Scroll down for historical charts and peer comparison views.

If Xenon Pharmaceuticals moved to the average analyst target of $78, shares would be roughly 33.2% higher than $58.19. Treat that as a sentiment and modeling checkpoint rather than a precise forecast, and weigh it against your own view of Xenon Pharmaceuticals's earnings trajectory.

Besides this target price page, Stockcircle has Xenon Pharmaceuticals's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect target price (currently $78) with ownership activity and broader fundamentals.

Xenon Pharmaceuticals's target price is $78; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.